Midatech Pharma PLC Result of AGM (8146U)
31 July 2020 - 11:48PM
UK Regulatory
TIDMMTPH
RNS Number : 8146U
Midatech Pharma PLC
31 July 2020
31 July 2020
Midatech Pharma PLC
("Midatech" or the "Company")
Result of 2020 Annual General Meeting
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
biodistribution of medicines, announces that at its Annual General
Meeting (AGM) held at 11.30am today, with the exception of
resolutions 6 (disapplication of pre-emption rights) and 7
(authority to purchase own shares) which failed to carry, all other
resolutions put to the meeting were duly passed by shareholders by
way of a poll.
With respect to resolution 6, 365,845 votes were cast for and
976,164 votes were cast against, representing 0.9% and 2.5% of
eligible votes respectively. With respect to resolution 7, 515,216
votes were cast for and 858,043 were cast against, representing
1.3% and 2.2% of eligible votes respectively.
The UK Placing, which was announced on 27 July 2020, is not
affected by the outcome of the voting above on the basis that
allotment of the Placing Shares and Broker Option Shares has been
made pursuant to existing share authorities which the Directors
were given at the Company's General Meeting held on 2 March
2020.
Unless otherwise stated, capitalised terms used in this
announcement have the meanings given to them in the announcement of
the UK Placing on 27 July 2020.
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Joint
Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Tel: +44 (0)20 7886 2500
Turner Pope Investments (TPI) Limited (Joint Broker, Sole
Bookrunner)
Andrew Thacker (Corporate Broking)
Tel: +44(0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Megan Paul / Laine Yonker
Tel: (646) 653-7030/ 7035
jgreen@edisongroup.com/ lyonker@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is an R&D company focused on 'Making Medicines Better'
by improving delivery of drugs in the body. The Company combines
existing medications with its proprietary and innovative drug
delivery technologies to provide compelling oncology and rare
disease products that have the potential to powerfully impact
the lives of patients undergoing treatment for life threatening
diseases.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading edge nanotechnology
used for targeting medications to sites of disease.
By improving bio-delivery and biodistribution of approved
existing molecules, Midatech's unique R&D has the potential
to make medicines better, lower technical risks, accelerate
regulatory approval and route to market, and provide newly
patentable products. The platform nature of the technologies
allows the potential to develop multiple drug assets rather
than being reliant on a limited number of programmes.
Midatech's technologies are supported by 36 patent families
including 120 granted patents and an additional 70 patent
applications.
Midatech's headquarters and R&D facility is in Cardiff, UK.
For more information please visit www.midatechpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGKKDBQNBKDOON
(END) Dow Jones Newswires
July 31, 2020 09:48 ET (13:48 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024